BGLAF (BioGaia AB) Accumulated Depreciation: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BGLAF BioGaia AB BGLAF
100 GF Score
Price $12.20
GF Value $13.14
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is BioGaia AB Accumulated Depreciation?

BioGaia AB BGLAF 100 Accumulated Depreciation is $0.0 Mil as of Jun. 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.14 (Fairly Valued). The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

BioGaia AB's quarterly accumulated depreciation declined from Dec. 2025 ($-22.9 Mil) to Mar. 2026 ($0.0 Mil) but then stayed the same from Mar. 2026 ($0.0 Mil) to Jun. 2026 ($0.0 Mil).

BioGaia AB's annual accumulated depreciation increased from Dec. 2023 ($-16.2 Mil) to Dec. 2024 ($-17.2 Mil) and increased from Dec. 2024 ($-17.2 Mil) to Dec. 2025 ($-22.9 Mil).

BioGaia AB Accumulated Depreciation Related Terms

BioGaia AB Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Accumulated Depreciation Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.46 -13.84 -16.16 -17.21 -22.86

BioGaia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -22.86 0.00 0.00
BGLAF
100GF Score
BioGaia AB BGLAF
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.0 Mil mean?
BioGaia AB (BGLAF) has a Accumulated Depreciation of $0.0 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on BioGaia AB and its competitors.
Is BioGaia AB's Accumulated Depreciation too high?
BioGaia AB's current Accumulated Depreciation is $0.0 Mil. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Accumulated Depreciation compare to ZTS?
BioGaia AB's Accumulated Depreciation of $0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on BioGaia AB and its competitors. BioGaia AB's current Accumulated Depreciation is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $13.14, compared to a current price of $12.20 — trading 7.2% below its estimated fair value. The current Accumulated Depreciation is $0.0 Mil. BioGaia AB's overall GF Score™ is 100/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Accumulated Depreciation is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGaia AB (BGLAF) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued. The current stock price of $12.20 is trading 7.2% below its estimated GF Value™ of $13.14. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BGLAF:

  • Accumulated Depreciation: $0.0 Mil
  • GF Value™: $13.14 vs. price of $12.20 (7.2% below fair value)
  • GF Score™: 100/100 with 3 warning signs

No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score

Get the complete analysis for BGLAF

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.20
Price
$13.14
GF Value